Molecular-based therapies for renal cell carcinoma

Related Experiment Video

Updated: Aug 8, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

A Zisman1, A J Pantuck, A S Belldegrun

  • 1University of California, School of Medicine, Department of Urology, Los Angeles 90095-1738, USA.

Current Urology Reports
|June 27, 2002
PubMed

Insights

Renal cell carcinoma (RCC) incidence is rising, with limited cures for metastatic disease. Understanding genetic and immune factors is key to developing new gene therapies and molecular treatments for better patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Rising incidence of renal cell carcinoma (RCC) presents a significant clinical challenge.
  • Current treatments for metastatic RCC have limited efficacy, necessitating novel therapeutic strategies.
  • Growing patient and institutional interest in gene therapy highlights its potential in oncology.

Purpose of the Study:

  • To review current gene therapies and related approaches for renal cell carcinoma.
  • To examine the genetic impairments and immune pathophysiology underlying RCC.
  • To identify ongoing clinical trials focused on molecular-based RCC therapies.

Main Methods:

  • Literature review of existing gene therapy research for RCC.
  • Analysis of studies on genetic and immune aspects of RCC.
  • Compilation of data from current clinical trials in molecular oncology.

Main Results:

  • Gene therapy and molecular approaches show promise for RCC treatment.
  • Understanding RCC's genetic and immune landscape is crucial for therapeutic development.
  • Numerous clinical trials are investigating novel molecular-based therapies for RCC.

Conclusions:

  • Advances in understanding RCC genetics and immunology are paving the way for innovative treatments.
  • Gene therapy and molecular-targeted treatments offer hope for improving outcomes in metastatic RCC.
  • Ongoing clinical trials are essential for translating research into effective patient care for RCC.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.